Why DBV Technologies Stock Popped Today
After hitting a major regulatory roadblock, DBV Technologies sees a path to approval for its leading candidate.
DBV Technologies(DBVT)
Nasdaq Global Select
DBVT
$5.21
$0.19
3.8%
Price as of March 5, 2021, 9:00 p.m. EST
View Interactive DBVT Charts
DBV Technologies S.A.
Interactive Chart
News & Analysis: DBV Technologies
Why DBV Technologies Stock Is Soaring Today
The company submitted its potential peanut allergy treatment for review in Europe.
Could This Small-Cap Biotech Stock Make You Rich?
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
Why DBV Technologies Stock Is Plunging Today
The FDA rejected the company’s application for its peanut-allergy patch.
Why DBV Technologies Is Plunging Today
The company provided a grim business update.
A Tale of 2 Biotechs With Competing Peanut Allergy Treatments
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
Why DBV Technologies Stock Is Plunging Today
A sizable capital raise sent shareholders running for the exits this morning.
Here's Why DBV Technologies Shares Jumped Higher Today
Long-term data suggests longer treatments with Viaskin Peanut improve peanut tolerance.
Why DBV Technologies Shares Soared Today
Traders cheered after the company announced the pricing details of a stock offering.
Why Conagra Brands, DBV Technologies, and Carnival Slumped Today
Find out why these stocks stood out on a down day for the market.
